Transcranial magnetic stimulation is now a mainstream option for people with depression that has not responded to medication. One of the most common questions patients and clinicians ask is whether the benefits last once a treatment course ends. A recent study focused on veterans with treatment resistant depression offers some of the clearest data yet on the durability of TMS response and provides reassurance about its long term value.
Why Durability Matters In Depression Treatment
Depression is often a chronic condition with a relapsing course. Many treatments reduce symptoms temporarily but lose effectiveness over time. Durability refers to how long patients remain well after treatment without severe relapse or the need for additional intensive interventions. For individuals who have already tried multiple medications, durability is especially important because repeated relapses can increase disability, suicide risk, and healthcare utilization.
What The New Veteran Study Examined
Researchers conducted a retrospective analysis of veterans who received TMS for treatment resistant major depressive disorder at a large Veterans Affairs medical center. Rather than relying only on symptom rating scales, the investigators used a clinically meaningful composite outcome called Significant Psychiatric Events Associated with Relapse. This measure included psychiatric hospitalization, suicide attempt, death by suicide, or the need for additional neuromodulation treatments.
This approach focused on real world outcomes that matter to patients, families, and health systems rather than short term symptom fluctuations.
Key Findings On Durable TMS Response In Depression
The results were striking. More than 84 percent of veterans who responded to TMS remained free of severe relapse for at least two years after completing treatment. Over one third of responders also went at least two years without needing major changes to their psychiatric medication regimen.
Importantly, no specific demographic or clinical factors predicted better or worse durability. This suggests that long lasting benefit was not limited to a narrow subgroup and may reflect a broadly robust treatment effect in this population.
Why These Results Are Clinically Meaningful
Veterans often have higher rates of comorbid conditions such as post traumatic stress disorder substance use disorders and medical illness. Demonstrating a durable TMS response in depression within this group strengthens confidence that TMS can offer sustained benefit even in complex and high risk populations.
The findings also support the idea that TMS may alter underlying brain networks involved in mood regulation rather than providing only short lived symptom relief. This aligns with neuroimaging and neurophysiology studies showing lasting changes in cortical excitability and connectivity after successful TMS treatment.
What This Means For Patients And Clinics
For patients considering TMS, these data help set realistic expectations. While not everyone responds, those who do have a high likelihood of maintaining benefit for years rather than months. For clinics and health systems, durable response supports the cost effectiveness of TMS by reducing hospitalizations, crisis interventions and the need for repeated treatment trials.
The study also highlights the importance of long term follow up and relapse monitoring rather than assuming that symptom improvement at treatment end tells the full story.
Remaining Questions And Next Steps
Although encouraging, the study was retrospective and conducted at a single center. Future prospective research will be important to confirm these findings, compare durability across different TMS protocols, and identify optimal strategies for maintenance or booster sessions when needed.
Still, the evidence strongly suggests that for many patients, TMS is not just an acute intervention but a treatment capable of producing lasting recovery.
Citations
- Lisha I, Godbole Kroger NB, Tsalatsanis A, et al. The durability of response to transcranial magnetic stimulation in veterans with major depressive disorder. Journal of Affective Disorders. 2025. https://pubmed.ncbi.nlm.nih.gov/41461238/
- Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The clinical TMS society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimulation. 2016. https://pubmed.ncbi.nlm.nih.gov/28029541/